Axiom ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4782-DZFS

BPC-157 / TB-500 (Wolverine) · Lot T-BPC-0025
Issued Oct 29, 2026 PT · v1
Verify: 9EA9-EF1C-AD7F

SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

L1	L2	L3	L4	L8
Identity	Purity	Net Peptide Content	Sterility	Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A · right

Brand	**Peptides For Less**	Product	**BPC-157 / TB-500 (Wolverine)**
Lot / Batch	**T-BPC-0025**	Label Claim	**BPC-157 10 mg + TB-500 10 mg**
Matrix	**lyophilized powder**	Sample Count	**1**
Cap Color	**Black**	Crimp Color	**Silver / Aluminum**
Contents Color	**White**	Seal Intact	**Yes**
Condition	**sealed, intact**	Received	**Sep 24, 2026 PT**
Sampling	**client submitted**		

Test Results

Test	Specification	Result	
Identity research screen	every declared component within ±1 Da of its own theoretical mass	2 of 2 components confirmed	PASS
Purity research screen	each declared component at or above its own locked purity criterion	99.85%	PASS
Net Peptide Content research screen	each declared component within its own locked content criterion, at the declared ratio	21.06 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4782-DZFS

BPC-157 / TB-500 (Wolverine) · Lot T-BPC-0025
Issued Oct 29, 2026 PT · v1
Verify: 9EA9-EF1C-AD7F

SCAN TO VERIFY

Layer Results

1 Identity
LC-MS (ESI+)

2 of 2 components confirmed — every declared component within ±1 Da of its own theoretical mass — PASS

Component	Its criterion	Observed	Status
BPC-157	1419.556 Da · acceptance ±1 Da · average	1419.7 Da · mass error +0.144 Da (101.4 ppm)	PASS
TB-500 (Thymosin B4)	4963.506 Da · acceptance ±1 Da · average	4963.559 Da · mass error +0.053 Da (10.7 ppm)	PASS

Acceptance: **within ±1 Da** · Vial A · **2 of 2 components confirmed**

2 Purity
RP-HPLC 214nm (USP 621)

99.85% — each declared component at or above its own locked purity criterion — PASS

Component	Its criterion	Observed	Status
BPC-157	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.94%	PASS
TB-500 (Thymosin B4)	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.76%	PASS

Acceptance: **Each component NLT 99.25 area %** · Vial A · **99.85% · PASS**

3 Net Peptide Content
Quantitative HPLC vs reference std

21.06 mg — each declared component within its own locked content criterion, at the declared ratio — PASS

Component	Its criterion	Observed	Status
BPC-157	9–11 mg (10 mg ±10%)	10.49 mg	PASS
TB-500 (Thymosin B4)	9–11 mg (10 mg ±10%)	10.57 mg	PASS

Ratio, in the table's component order: observed **1.00 : 1.01** against declared **1.00 : 1.00** · source Axiom SPEC-CONTENT-001
Target: **20 mg (±10%)**

4 Sterility · Rapid PCR
Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected — Rapid PCR screen — PASS

8 Fentanyl Screen
LC-MS/MS targeted adulterant screen

none detected — no fentanyl or analog at or above 1 ng/mg — PASS

Result: **Not detected** · Detection limit: **1 ng/mg**
Analytes screened: **Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)** · Source container: **A**

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Peptides

SCAN TO VERIFY

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4782-DZFS

BPC-157 / TB-500 (Wolverine) · Lot T-BPC-0025
Issued Oct 29, 2026 PT · v1
Verify: 9EA9-EF1C-AD7F

Reporting Scope & Limitations

`[Sterility · Rapid PCR]` Rapid PCR screen for microbial DNA. It detects DNA from live and dead organisms and is not a USP <71> sterility test or a USP <61> count. Full USP <71> sterility testing is available as an add-on.

`[Fentanyl Screen]` Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	**Alana Reeves**	Analyst Signature	**ed25519:b7c51970bec0ec48194cadbc...**
Technical Reviewer	**Michael Niles**	Reviewer Signature	**ed25519:9e2d5919223e69355a53bf97...**
Laboratory Director	**Daniel Brennan**	Director Signature	**ed25519:9e86f23c5f33cf79104aaf07...**

Testing is performed within Axiom's laboratory network under Axiom's methods. Every result is reviewed and released by Axiom, which issues and is responsible for this certificate. Axiom Analytics does not hold ISO/IEC 17025 accreditation. Samples are identified to the testing laboratory by an internal lot ID only. The method status of each result is shown beside it.

Each signature is an Ed25519 signature over the SHA-384 hash of this report. Scan the QR code or verify it yourself at https://axiomanalyticslab.com/verify/AX-2026-4782-DZFS.

✓ **CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)**

`SHA-384: f228ba07b07524b26526571e599b3e82f7b1f27579fd2f26cb76d3f6a5ec62af...`

`Seal: ed25519:338eb4c3dabd6078d89277466525780479253 02b...`

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.